Omega-3-Acid Ethyl Esters
Metabolic Dysfunction-Associated Steatotic Liver Disease
Explore 131 assets in Metabolic Dysfunction-Associated Steatotic Liver Disease →Floatz Rating
B61/100
Confidence
Indicative
Sponsor
University of Edinburgh
Modality
mixture
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01277237CT.gov The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease | — | Completed | — | — | — |
NCT00760513CT.gov Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids | — | Completed | — | — | — |
NCT00941642CT.gov Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease | — | Unknown | — | — | — |
NCT00694746CT.gov Study of Fish Oil to Reduce ALT Levels in Adolescents | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatotic Liver Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Omega-3-Acid Ethyl Esters (this asset) | University of Edinburgh | Approved | B · 61 |
| Dapagliflozin | Post Graduate Institute of Medical Education and Research, Chandigarh | P4 | BBB |
| Metformin | Xiqiao Zhou | P4 | BBB |
| Exenatide | Fudan University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Empagliflozin | Justin Ryder | P4 | BBB |
| Tirzepatide | Regeneron Pharmaceuticals | P3 | BBB |
| Ervogastat | Pfizer | P2 | BB |
| Clesacostat | Columbia University | P2 | BB |
+42 more in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort
Other indications for Omega-3-Acid Ethyl Esters
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizoaffective Disorder | — | P4 | B · 58 |
| HIV Infectious Disease | — | P4 | B · 58 |
| Bipolar Disorder | — | P4 | CCC · 55 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Omega-3-Acid Ethyl Esters in Metabolic Dysfunction-Associated Steatotic Liver Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/omega-3-acid-ethyl-esters-metabolic-dysfunction-associated-steatotic-liver-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →